Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KMD-110
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
KMD-110 is a recombinant fusion protein consisting of a human epidermal growth factor receptor 2 (HER2) targeting affibody fused to glutathione S-transferase (GST). Originally developed by Fusion Biotech and licensed to KMD Bio, KMD-110 is designed to selectively bind to HER2-expressing cancer cells. The GST domain of the fusion protein serves as a bio-linker that can interact with glutathione (GSH) for controlled drug delivery or act as a targeting moiety. KMD-110 is being investigated for the treatment of HER2-expressing solid tumors, including gastric cancer, lung cancer, and breast cancer.
- Other names
- HER2-Affibody-GSTHER-2-Affibody-GSTHER 2-Affibody-GST
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on KMD-110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KMD-110.